BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34931765)

  • 1. MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis
    Yan F; Wang Q; Xia M; Ru Y; Hu W; Yan G; Xiong X; Zhang M; Wang J; Li Q; Zhang B; Wang H; Lin W; Wu G; Li X
    Cancer Biol Med; 2021 Dec; 19(6):818-35. PubMed ID: 34931765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice.
    Hoefflin R; Harlander S; Schäfer S; Metzger P; Kuo F; Schönenberger D; Adlesic M; Peighambari A; Seidel P; Chen CY; Consenza-Contreras M; Jud A; Lahrmann B; Grabe N; Heide D; Uhl FM; Chan TA; Duyster J; Zeiser R; Schell C; Heikenwalder M; Schilling O; Hakimi AA; Boerries M; Frew IJ
    Nat Commun; 2020 Aug; 11(1):4111. PubMed ID: 32807776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromodomain-containing protein 9 is a prognostic biomarker associated with immune infiltrates and promotes tumor malignancy through activating notch signaling pathway in negative HIF-2α clear cell renal cell carcinoma.
    Lou W; Gao K; Xu C; Li Q
    IUBMB Life; 2021 Nov; 73(11):1334-1347. PubMed ID: 34415102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TBC1D5 reverses the capability of HIF-2α in tumor progression and lipid metabolism in clear cell renal cell carcinoma by regulating the autophagy.
    Huang Y; Xiong Z; Wang J; Gao Y; Cao Q; Wang D; Shi J; Chen Z; Yang X
    J Transl Med; 2024 Feb; 22(1):212. PubMed ID: 38419050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma.
    Zhang ZY; Zhang SL; Chen HL; Mao YQ; Li ZM; Kong CY; Han B; Zhang J; Chen YH; Xue W; Zhai W; Wang LS
    Cell Prolif; 2020 Jul; 53(7):e12853. PubMed ID: 32537867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
    Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
    Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high
    Miikkulainen P; Högel H; Seyednasrollah F; Rantanen K; Elo LL; Jaakkola PM
    J Biol Chem; 2019 Mar; 294(10):3760-3771. PubMed ID: 30617181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
    Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D
    Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
    Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
    PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
    Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
    J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
    Petrella BL; Brinckerhoff CE
    Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIF-2α/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma.
    Xiao H; Qu Y; Li H; Zhang Y; Fei M; Liang C; Yang H; Zhang X
    J Exp Clin Cancer Res; 2024 Jan; 43(1):29. PubMed ID: 38263248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
    Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma.
    Liu Y; Tan X; Liu W; Chen X; Hou X; Shen D; Ding Y; Yin J; Wang L; Zhang H; Yu Y; Hou J; Thompson TC; Cao G
    Chin J Cancer; 2018 Jan; 37(1):2. PubMed ID: 29357946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of HIF‑α and their association with clinicopathological parameters in clinical renal cell carcinoma.
    Sitaram RT; Ljungberg B
    Ups J Med Sci; 2024; 129():. PubMed ID: 38571885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.